Filing Flows › Silence Therapeutics (SLN) › Q1 2026
Silence Therapeutics (SLN) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 7, 2026
Silence Therapeutics (SLN) reported revenue of $422K for the first quarter 2026 (Q1 2026), +197% from a year earlier and up 12-fold from the quarter before.
Silence Therapeutics, Q1 2026: revenue $422K (+197% year over year), net loss $15.0M, operating cash flow −$15.6M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $422K | 12× | +197% |
| Operating profit | −$15.7M | — | — |
| Net earnings | −$15.0M | — | — |
| Operating cash flow | −$15.6M | — | — |
What changed
Revenue was $422K in Q1 2026, up 197% year over year and up 1141% from the previous quarter.
Gross margin was 97.4%, up 35.4 points from Q1 2025. Operating costs exceeded revenue by $15.7M, an operating margin of -3729.1%. Operating expenses fell 43% while revenue rose 197%. The quarter ended with a net loss of $15.0M, wider than the previous quarter's $11.8M loss.
Operating cash flow was −$15.6M. Non-cash charges added back $72K of depreciation and $2.4M of share-based compensation. Working capital and other items used $3.2M.
Questions
What was Silence Therapeutics' revenue in the first quarter 2026?
Silence Therapeutics (SLN) reported revenue of $422K for the first quarter 2026 (Q1 2026), +197% from a year earlier and up 12-fold from the quarter before.